|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
AU4093799A
(en)
|
1998-05-22 |
1999-12-13 |
Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and therapies based thereon
|
|
US8617514B2
(en)
|
1999-02-22 |
2013-12-31 |
Georgetown University |
Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
|
|
JP2002541255A
(ja)
|
1999-04-09 |
2002-12-03 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物
|
|
AU2002228772B2
(en)
|
2000-11-02 |
2005-12-08 |
Sloan Kettering Institute For Cancer Research |
Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors
|
|
US7671010B2
(en)
|
2002-08-30 |
2010-03-02 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
|
|
AU2002364566B2
(en)
|
2001-12-12 |
2009-03-26 |
Conforma Therapeutics Corporation |
Assays and implements for determining and modulating HSP90 binding activity
|
|
GB0211578D0
(en)
|
2002-05-21 |
2002-06-26 |
Univ Belfast |
Medicaments
|
|
US7769423B2
(en)
|
2002-09-11 |
2010-08-03 |
Duke University |
MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
|
|
AU2003303058A1
(en)
|
2002-12-12 |
2004-07-09 |
Conforma Therapeutics Corporation |
Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
|
|
CA2560822A1
(en)
|
2004-03-26 |
2005-10-13 |
Van Andel Research Institute |
Geldanamycin and derivatives inhibit cancer invasion and identify novel targets
|
|
US7834181B2
(en)
|
2005-02-01 |
2010-11-16 |
Slaon-Kettering Institute For Cancer Research |
Small-molecule Hsp90 inhibitors
|
|
WO2007053792A2
(en)
|
2005-11-05 |
2007-05-10 |
Amplyx Pharmaceuticals, Inc. |
Improving the pharmacokinetics of protease inhibitors and other drugs
|
|
WO2007064691A1
(en)
|
2005-12-02 |
2007-06-07 |
Nabil Habib Lab |
Treatment of cancer and other diseases
|
|
GB0526615D0
(en)
|
2005-12-30 |
2006-02-08 |
Novartis Ag |
Organic compounds
|
|
WO2008005937A2
(en)
|
2006-06-30 |
2008-01-10 |
Sloan-Kettering Institute For Cancer Research |
Treatment of neurodegenerative diseases through inhibiton of hsp90
|
|
EP2073802A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
JPWO2008108386A1
(ja)
*
|
2007-03-05 |
2010-06-17 |
協和発酵キリン株式会社 |
医薬組成物
|
|
US20120003160A1
(en)
|
2007-06-29 |
2012-01-05 |
Amag Pharmaceuticals, Inc. |
Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
|
|
WO2009009067A2
(en)
*
|
2007-07-09 |
2009-01-15 |
Kwon Glen S |
Micelle encapsulation of theropeutic agents
|
|
JP2011501731A
(ja)
|
2007-09-10 |
2011-01-13 |
ユニバーシティ オブ マサチューセッツ |
ミトコンドリア標的化抗腫瘍剤
|
|
WO2010028389A1
(en)
|
2008-09-08 |
2010-03-11 |
The Methodist Hospital Research Institute |
Image-guided energy deposition for targeted drug delivery
|
|
WO2011116181A1
(en)
|
2010-03-17 |
2011-09-22 |
Caris Life Sciences, Inc. |
Theranostic and diagnostic methods using sparc and hsp90
|
|
ES3029483T3
(en)
|
2008-09-17 |
2025-06-24 |
Endocyte Inc |
Folate receptor binding conjugates of antifolates
|
|
WO2010056590A2
(en)
|
2008-11-14 |
2010-05-20 |
University Of Maryland, Baltimore |
Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging
|
|
JP5764127B2
(ja)
|
2009-08-17 |
2015-08-12 |
ロシュ グリクアート アーゲー |
標的化イムノコンジュゲート
|
|
WO2011133879A2
(en)
|
2010-04-22 |
2011-10-27 |
University Of Massachusetts |
Combination therapies with mitochondrial-targeted anti-tumor agents
|
|
US20120064107A1
(en)
*
|
2010-05-18 |
2012-03-15 |
Cerulean Pharma Inc. |
Compositions and methods for treatment of autoimmune and other disease
|
|
US20120213854A1
(en)
*
|
2010-09-30 |
2012-08-23 |
Fetzer Oliver S |
Methods of treating a subject and related particles, polymers and compositions
|
|
US20140031302A1
(en)
|
2010-10-22 |
2014-01-30 |
Universite De Strasbourg |
Pochoxime conjugates useful for the treatment of hsp90 related pathologies
|
|
US20130331357A1
(en)
*
|
2011-01-11 |
2013-12-12 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
|
|
CN104126017A
(zh)
*
|
2011-11-11 |
2014-10-29 |
米伦纽姆医药公司 |
对蛋白酶体抑制剂的反应的生物标记
|
|
US20140079636A1
(en)
*
|
2012-04-16 |
2014-03-20 |
Dinesh U. Chimmanamada |
Targeted therapeutics
|
|
US9598503B2
(en)
*
|
2012-04-18 |
2017-03-21 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
|
CN104640572B
(zh)
|
2012-05-15 |
2018-04-27 |
索伦托医疗有限公司 |
药物偶联物，偶联方法，及其用途
|
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
EP3738594A1
(en)
|
2013-09-10 |
2020-11-18 |
Madrigal Pharmaceuticals, Inc. |
Targeted therapeutics having an hsp90 ligand as binding moiety
|
|
KR102087850B1
(ko)
|
2013-10-11 |
2020-03-12 |
메르사나 테라퓨틱스, 인코포레이티드 |
단백질-고분자-약물 접합체
|
|
AU2014337317A1
(en)
|
2013-10-15 |
2016-09-15 |
Sorrento Therapeutics Inc. |
Drug-conjugates with a targeting molecule and two different drugs
|
|
WO2015066053A2
(en)
|
2013-10-28 |
2015-05-07 |
Synta Pharmaceuticals Corp. |
Targeted therapeutics
|
|
US11007183B2
(en)
|
2013-12-20 |
2021-05-18 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors
|